Technical founders approach investor meetings with a disadvantage that is rarely acknowledged and frequently fatal to the pitch. They have spent years developing deep expertise in a domain that most investors do not fully understand, and they have learned, correctly, that rigour and precision are the currencies of credibility in scientific and engineering environments. When they sit across the table from an investor, they apply the same standards. They lead with the mechanism. They qualify every claim. They present data carefully and avoid overstating conclusions. They are, in other words, doing exactly what their training has taught them to do.
Investors are not evaluating them on those criteria. They are asking a different set of questions entirely, and the mismatch between what technical founders present and what investors need to understand is one of the most consistent and preventable causes of fundraising failure in the STEM startup ecosystem.
This is not an argument for founders to become less rigorous or to overstate their science. Scientific credibility is a genuine competitive advantage in a market where investors have been burned by technical claims that did not survive scrutiny. The argument is more precise: technical founders need to understand the specific questions investors are trying to answer, and structure their presentation of the science and the business to answer those questions directly, without sacrificing the credibility that makes the science worth believing.
The investor’s decision framework
Investors are not evaluating startups on an absolute scale. They are making relative allocation decisions across a portfolio of opportunities, under conditions of significant uncertainty, with limited time to develop conviction. Understanding this changes how a pitch should be constructed.
An investor considering a STEM startup is trying to answer five questions, roughly in this order. Is the problem real and large enough to support a significant business? Is this team capable of solving it? Is the technical approach credible and defensible? Is there a path to returns that is consistent with the fund’s investment thesis? And is now the right time, and is this the right moment in the company’s development to invest?
Most technical founders spend the majority of their pitch time on the third question, the technical approach, and insufficient time on the first, second, fourth, and fifth. The result is a pitch that is scientifically coherent and commercially incomplete. Investors who cannot answer all five questions with reasonable confidence will not invest, regardless of how compelling the technical content is.
The problem before the solution
The most common structural error in technical founder pitches is leading with the solution before establishing the problem. Founders who have spent years developing a technology are deeply familiar with what it does and how it works. They assume that the significance of the problem it solves is self-evident. It rarely is to an investor who is seeing the company for the first time.
A problem statement that works for investors needs to do three things. It needs to establish that the problem is real, with evidence from the market rather than from the founders’ own conviction. It needs to establish that the problem is large enough to support a significant business, which means quantifying the addressable market in a way that is grounded and specific rather than derived from generic top-down estimates. And it needs to establish that existing solutions are genuinely inadequate, not merely suboptimal, so that the case for a new approach is clear.
This last point deserves particular attention in STEM sectors. Investors in healthtech, medtech, and diagnostics have seen many pitches in which the incumbent solution is presented as inadequate on technical grounds that are real but commercially irrelevant. A diagnostic tool that is ten percent more sensitive than the current standard is a scientific improvement. Whether it is a commercial opportunity depends entirely on whether that sensitivity improvement translates into meaningfully better patient outcomes, whether clinicians will change their behaviour to use it, whether payers will reimburse it at a price that supports the business model, and whether the regulatory pathway is proportionate to the commercial opportunity. Technical founders who lead with the sensitivity improvement without addressing these questions are answering the wrong question for the investor audience.
Team credibility without credential overload
Investors invest in teams as much as they invest in technologies, and team slides are among the most consequential and most poorly constructed elements of most technical founder pitches. The error is almost always the same: a list of credentials that establishes that the founders are qualified scientists or engineers, but does not establish that they are capable of building a business.
A PhD from a leading university and a publication record in a high-impact journal are genuine signals of technical credibility. They do not answer the question an investor is actually asking, which is: has this team demonstrated the ability to make commercial decisions, manage stakeholders, respond to setbacks, and build an organisation under conditions of uncertainty and resource constraint?
The credentials that answer this question are different. Evidence of prior commercial experience, including failures that were navigated intelligently, matters more than publication count. Evidence of the ability to recruit and retain people outside the founding team signals organisational capability. Evidence of customer or clinical partner engagement, even at early stage, demonstrates that the team can operate in a commercial environment and that the product has external validation beyond the founders’ own assessment.
For technical founders who lack extensive commercial track records, the framing of the team slide needs to work harder. The question is not what credentials the team has, but what those credentials enable the team to do that competitors cannot. A founding team that combines deep domain expertise with specific prior experience of the regulatory pathway, the clinical development process, or the investor landscape in the relevant sector is a different proposition from a team of excellent scientists who have not yet encountered these challenges. The distinction needs to be explicit.
The commercial logic of the technical approach
Technical founders frequently present their technology in terms of what it does rather than what it enables commercially. These are related but distinct framings, and the distinction matters significantly for how investors assess the opportunity.
What a technology does is a scientific statement. What it enables commercially is a business statement. Investors need both, but they need the business statement first. A diagnostic platform that uses proprietary AI to identify biomarkers associated with early-stage fibrosis is a technical description. A diagnostic platform that enables gastroenterologists to identify patients with early-stage fibrosis before they progress to cirrhosis, reducing the cost of disease management and creating a clear reimbursement case in markets where cirrhosis treatment costs are well established, is a commercial description. The underlying technology may be identical. The investor’s ability to assess the opportunity is not.
The commercial logic of a technical approach also needs to address the competitive moat: the reasons why the technical advantage is durable rather than temporary. In STEM sectors, the most credible moats are typically combinations of proprietary data, regulatory clearance, clinical validation, and network effects in the clinical or customer base, rather than the underlying algorithm or engineering approach, which can in principle be replicated. Investors who have seen multiple STEM companies will probe this question specifically, and founders who have not thought carefully about it will be exposed in the meeting.
The financial model as a statement of understanding
Most seed and early Series A investors do not believe the revenue projections in a startup’s financial model. They know the projections will be wrong. The model is not primarily a forecast. It is a statement of how thoroughly the founding team understands the economics of the business they are building, and a framework for the conversation about assumptions.
A financial model that works for investors at seed and Series A stage needs to demonstrate four things. First, that the founding team understands the unit economics of the business: the cost of acquiring a customer, the revenue generated per customer, the margin structure, and the payback period. Second, that the key assumptions driving the model are explicit, defensible, and grounded in market evidence rather than aspiration. Third, that the model connects logically to the use of proceeds from the raise: the money raised funds specific activities that produce specific outcomes that support the valuation at the next round. Fourth, that the model stress-tests cleanly: the business is viable under pessimistic assumptions about key variables, not only under base case assumptions.
STEM founders often present financial models that are technically sophisticated and commercially naive. The unit economics are modelled at the level of the underlying technology rather than the commercial product. The key assumptions are derived from scientific parameters rather than market data. The connection between the raise and the next milestone is implicit rather than explicit. These are not errors of competence. They are errors of framing, and they are correctable with the right preparation.
The timing question
The fifth question investors are trying to answer, whether now is the right time, is the one most frequently neglected in technical founder pitches, and it is the one that most directly determines whether an investor moves forward quickly or defers.
The timing question has two dimensions. The first is market timing: why is this problem becoming more important now, and why is the window for a new solution opening at this moment rather than five years ago or five years from now. For STEM companies, market timing is often driven by changes in the regulatory environment, new reimbursement policies, advances in enabling technologies such as AI or genomic sequencing, or shifts in clinical practice. Founders who can articulate a specific and credible reason why the timing is right now are significantly more compelling than those who present their technology as timeless.
The second dimension is company timing: why is this the right moment in the company’s development to raise this round, and what will the company look like at the end of the funding period. Investors are not just evaluating the current state of the business. They are evaluating whether the proposed round gets the company to a position from which it can raise its next round at a meaningfully higher valuation. If the proposed use of proceeds does not get the company to a clear and credible next milestone, the round is not well constructed.
Technical founders who can answer all five of these questions with clarity, precision, and commercial fluency, without overstating the science and without burying the commercial logic under technical detail, are the founders who close rounds efficiently. The science does not need to be simplified. It needs to be contextualised within a commercial argument that investors can evaluate on their own terms.
David Weiss is Director of Fundraising and Commercial Strategy at GoldWhite. He holds a PhD in Engineering from the University of Cambridge, previously worked as an equity derivatives trader at Goldman Sachs and an M&A analyst at Leonardo & Co., and has raised over £6M for clients across investment rounds and grant applications.